| Literature DB >> 31439719 |
Shuo Zhang1,2, Fan Liang3, Caixia Lei1, Junping Wu1, Jing Fu1, Qi Yang3, Xiao Luo3, Guoliang Yu3, Depeng Wang3, Yueping Zhang1, Daru Lu2, Xiaoxi Sun4,5, Yu Liang6, Congjian Xu4,5.
Abstract
BACKGROUND: Preimplantation genetic testing (PGT) has already been applied in patients known to carry chromosomal structural variants to improve the clinical outcome of assisted reproduction. However, conventional molecular techniques are not capable of reliably distinguishing embryos that carry balanced inversion from those with a normal karyotype. We aim to evaluate the use of long-read sequencing in combination with haplotype linkage analysis to address this challenge.Entities:
Keywords: Oxford Nanopore technology; genome-wide haplotype analysis; long-read sequencing; pathogenic structural variants; preimplantation genetic testing
Mesh:
Year: 2019 PMID: 31439719 PMCID: PMC6860410 DOI: 10.1136/jmedgenet-2018-105976
Source DB: PubMed Journal: J Med Genet ISSN: 0022-2593 Impact factor: 6.318
Detailed results of microarray platform of the biopsied blastocysts
| Patient | Biopsied blastocysts, n | Grade of blastocysts | Molecular karyotype | Predictive results | Karyotype of amniotic fluid | |
|
|
| |||||
| Patient 1 | Embryo 1 | 5BC | UPD (1–22,X) | NA | NA | |
| Embryo 7 | 5BC | (1–22)*2, (XN)*1 | Carrier | NA | No pregnancy | |
| Embryo 8 | 5BB | (1–22)*2, (XN)*1 | Carrier | NA | Carrier | |
| Embryo 9 | 6BB | 5*3; 10*3 | Normal | NA | ||
| Patient 2 | Embryo 1 | 5BC | (1–22)*2, (XN)*1 | NA | Normal | Normal |
| Embryo 6 | 5AB | 1p36.33p21.3*1; 1q31.3q44*3 | NA | Unbalanced | ||
| Embryo 7 | 5BC | 1p36.33p21.3*3; 1q31.3q44*1 | NA | Unbalanced | ||
| Embryo 10 | 5BC | 1p36.33p21.3*1; 1q31.3q44*3 | NA | Unbalanced | ||
| Patient 3 | Embryo 1 | 5BC | (1–22)*2, (XN)*1 | Carrier | NA | Carrier |
| Embryo 2 | 5BC | (1–22)*2, (XN)*1 | Carrier | NA | Not transplanted | |
| Patient 4‡ | Embryo 1-1 | 5BB | 19*1 | Normal | NA | |
| Embryo 1-2 | 6BB | 7p22.3*3; 7q32.3q36.3*1; 15*3 | Carrier | Unbalanced | ||
| Embryo 2-1 | 5CB | (1–22)*2, (XN)*1 | Normal | Normal | No pregnancy | |
| Embryo 2-3 | 5CB | (1–22)*2, (XN)*1 | Carrier | Carrier | Carrier | |
| Embryo 2-5 | 5CB | (1–22)*2, (XN)*1 | Carrier | Carrier | Not transplanted | |
| Embryo 2-6 | 5BC | 7p22.3*3; 7q32.3q36.3*1 | Carrier | Unbalanced | ||
| Embryo 2-8 | 5BB | 22*1 | Normal | Normal | ||
| Embryo 2-10 | 5BC | 14*1 | Carrier | Carrier | ||
*In patients 1, 3 and 4, family member was used as a reference to phase haplotype analysis to predict the karyotype of diploid embryo.
†In patients 2 and 4, the unbalanced embryo was used as a reference to phase haplotype analysis to predict the karyotype of diploid embryo. In patient 2, embryos 6, 7 and 10 were used as a reference; in patient 4, embryo 1-2 and embryo 2-6 were used as a reference.
‡In patient 4, the embryos were from two COH cycles, embryo 1-1 and embryo 1-2 were from the first COH cycle, the other embryos were from the second COH cycle.
COH, controlled ovarianhyper-stimulation; NA, not applicable.
Figure 1The study designation and workflow. (A) The genetic map of an example of the recruited family, all the genetic maps of the four families were included. (B) Flow chart of the experiment and bioinformatics pipeline, the process is universal for all patients. CCS, comprehensive chromosomal screening; SV, structural variation; QC, quality control.
Summary of break point characterisation results of the patients by Nanopore and Sanger sequencing
| Patient | Karyotype of peripheral blood cells | Depth | Mapped sequencing reads, n | Mapped sequencing bases, n | Coverage rate (%) | Spanning break points reads, n | Break point position verified by Sanger sequencing | Inversed segment length (%) | Disrupted gene |
| Patient 1 | 46,XX,inv(4)(p14q27) mat | 10.09 | 1 706 982 | 29 835 157 259 | 90.29 | 8 | 4p:48457185 to 48457191 | 68.8 Mb (36.17) | Intergenic region |
| Patient 2 | 46,XY,inv(1)(p13;q25) de novo | 9.31 | 1 589 787 | 26 831 139 403 | 90.57 | 11 | 1p:95878134 | 97.6 Mb (39.19) | Intergenic region |
| Patient 3 | 46,XY,inv(10)(q11.2q21) mat | 10.63 | 2 219 769 | 30 186 409 140 | 90.78 | 7 | 10q:45936726 | 15.1 Mb (11.14) | ALOX5 (intron 8/13) |
| Patient 4 | 46,XY,inv(7)(p15q22) mat | 10.36 | 1 802 605 | 29 435 219 925 | 90.76 | 8 | 7p:2538312 to 2538322 | 129.6 Mb (81.34) | Intergenic region |
Reference sequence: GRCH37/hg19 reference genome.
Figure 2Large inversion variants detected by Nanopore long-read sequencing technology. Four cases, patients 1–4, were represented by (A), (B), (C) and (D), respectively. For each case, the top panel figured the chromosome which inversion occurred supported by karyotype results, and long-read (LR) alignments coving the break points. Two parts of the split reads were denoted by blue (forward) and red (reverse). The panel in the bottom shows short-read alignments (BWA-MEM; IGV-SR) and long-read alignments (ngmlr; IGV-LR) around break points using Integrative Genomics View (IGV). All the break points, three of eight located in repeat region, were supported by short and long reads, except one in patient 4, DEL-INV-DEL, was missed by callers by using short reads. DEL, deletion; INV, inversion; RC, Rolling Circle; SINE, Short interspersed nuclear elements.
Figure 3PCR and Sanger sequencing validated inversion variants detected by Nanopore long-read sequencing technology. (A) PCR validation of inversion variants. PCR products of the four patients and the normal control were shown in the top and bottom parts, respectively. For each individual, four fragments, two break point junctions (BJ1 and BJ2) and two normal alleles (N1 and N2), were validated. (B) Four schematic diagrams displayed precise break points identified by Sanger sequencing.
Summary of informative SNPs used to establish the haplotypes of the diploid blastocysts
| Patient | Embryo No | Break point position | Total number of informative SNPs in break point ±2 Mb | Total number of informative SNPs in chromosome | Average number of informative SNPs/Mb in chromosome | Total number of recombination SNPs in chromosome | Location of recombination in chromosome | Whether recombination happens in the break point regions |
| Patient 1 | Embryo 7 | 4p:48457185 | 57 | 1236 | 6.5 | 0 | No recombination | No |
| 4q:117253984 | 18 | |||||||
| Embryo 8 | 4p:48457185 | 58 | 1239 | 6.5 | 0 | No recombination | No | |
| 4q:117253984 | 18 | |||||||
| Patient 2 | Embryo 1 | 1p:95878134 | 24 | 658 | 6.7 | 146 | 1:171239912–191311571 (q24.3q31.2) | No |
| Embryo 1 | 1q:193437149 | 32 | ||||||
| Patient 3 | Embryo 1 | 10q:45936726 | 12 | 1054 | 7.9 | 50 | 10:1–4117294 (p15.3p15.1) | No |
| 10q:61040107 | 13 | |||||||
| Embryo 2 | 10q:45936726 | 8 | 905 | 6.8 | 45 | 10:131606042–135534747 (q26.3) | No | |
| 10q:61040107 | 12 | |||||||
| Patient 4 | Embryo 2-1 | 7p:2538312 | 28 | 1141 | 7.2 | 106 | 7:145572556–159138663 (q35q36.3) | No |
| 7q:132149320 | 21 | |||||||
| Embryo 2-3 | 7p:2538312 | 23 | 1146 | 7.2 | 0 | No recombination | No | |
| 7q:132149320 | 23 | |||||||
| Embryo 2-5 | 7p:2538312 | 21 | 1087 | 6.8 | 0 | No recombination | No | |
| 7q:132149320 | 20 |